- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03664752
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
March 3, 2023 updated by: Bausch Health Americas, Inc.
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel at Weeks 2, 4, 8, and 12.
To be eligible for the study subjects must be at least 9 years of age and have a clinical diagnosis of moderate to severe acne
Study Type
Interventional
Enrollment (Actual)
585
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Waterloo, Ontario, Canada, N2J 1C4
- Valeant Site 219
-
Waterloo, Ontario, Canada, N2J 1C4
- Valeant Site 228
-
-
-
-
Arkansas
-
Rogers, Arkansas, United States, 72758
- Valeant Site 210
-
-
California
-
Manhattan Beach, California, United States, 90266
- Valeant Site 201
-
San Diego, California, United States, 92123
- Valeant Site 206
-
San Diego, California, United States, 92123
- Valeant Site 218
-
-
Florida
-
Boynton Beach, Florida, United States, 33437
- Valeant Site 204
-
Brandon, Florida, United States, 33511
- Valeant Site 217
-
Miami, Florida, United States, 33144
- Valeant Site 202S
-
Tampa, Florida, United States, 33606
- Valeant Site 214
-
-
Georgia
-
Snellville, Georgia, United States, 30078
- Valeant Site 222
-
-
Idaho
-
Boise, Idaho, United States, 83704
- Valeant Site 215
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Valeant Site 205
-
-
Michigan
-
Clarkston, Michigan, United States, 48346
- Valeant Site 216
-
Clinton Township, Michigan, United States, 48038
- Valeant Site 221
-
-
New York
-
Rochester, New York, United States, 14623
- Valeant Site 227
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Valeant Site 229
-
Raleigh, North Carolina, United States, 27612
- Valeant Site 230
-
-
Texas
-
San Antonio, Texas, United States, 78213
- Valeant Site 213
-
-
Washington
-
Spokane, Washington, United States, 99202
- Valeant Site 223
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
9 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female at least 9 years of age and older;
- Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit);
- Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity Score (EGSS) assessment at the baseline visit;
- Subjects with facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20 but no more than 50;
- Subjects with facial acne non-inflammatory lesion (open and closed comedones) count no less than 25 but no more than 100;
- Subjects with two or fewer facial nodules
Exclusion Criteria:
- Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;
- Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, eczema;
- Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
- Subjects with a facial beard or mustache that could interfere with the study assessments;
- Subjects with more than two (2) facial nodules;
- Evidence or history of cosmetic-related acne
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IDP-120 Gel
IDP-120 Gel, once-daily application
|
IDP-120 Gel, once-daily application
|
Placebo Comparator: IDP-120 vehicle gel
IDP-120 vehicle gel, once daily application
|
IDP-120 Vehicle Gel, once-daily application
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute Change in Mean Lesion Counts at Week 12
Time Frame: Baseline to Week 12
|
For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count.
For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately.
|
Baseline to Week 12
|
Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS) and Had an EGSS at Week 12 That Equated to "Clear" or "Almost Clear"
Time Frame: Baseline to Week 12
|
Evaluator's Global Severity Score (EGSS) was determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris.
Evaluations were scored on a scale of 0-4, with 0 being clear and 4 being severe.
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in Mean Lesion Counts at Week 12
Time Frame: Baseline to Week 12
|
For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count.
For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately.
|
Baseline to Week 12
|
Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS)
Time Frame: Baseline to Week 12
|
Evaluator's Global Severity Score (EGSS) was determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris.
Evaluations were scored on a scale of 0-4, with 0 being clear and 4 being severe.
|
Baseline to Week 12
|
Percentage Change in Mean Lesion Counts at Week 8
Time Frame: Baseline to Week 8
|
For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count.
For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately.
|
Baseline to Week 8
|
Percentage Change in Mean Lesion Counts at Week 4
Time Frame: Baseline to Week 4
|
For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count.
For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately.
|
Baseline to Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Anya Loncaric, Bausch health companies
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 10, 2018
Primary Completion (Actual)
May 7, 2020
Study Completion (Actual)
May 7, 2020
Study Registration Dates
First Submitted
September 6, 2018
First Submitted That Met QC Criteria
September 6, 2018
First Posted (Actual)
September 10, 2018
Study Record Updates
Last Update Posted (Actual)
March 29, 2023
Last Update Submitted That Met QC Criteria
March 3, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V01-120A-302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
PollogenLumenis Be Ltd.Not yet recruitingModerate to Severe Acne Vulgaris
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
-
Assiut UniversityCompleted
-
Sebacia, Inc.CompletedFacial Acne VulgarisDenmark, Switzerland
Clinical Trials on IDP-120 Gel
-
Bausch Health Americas, Inc.CompletedAcne VulgarisUnited States, Canada
-
Valeant PharmaceuticalsUnknown
-
Bausch Health Americas, Inc.CompletedAcne VulgarisUnited States, Canada
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedAcne VulgarisUnited States, Canada
-
Bausch Health Americas, Inc.CompletedAcne VulgarisUnited States, Canada
-
Bausch Health Americas, Inc.CompletedAcne VulgarisUnited States, Canada
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedAcne VulgarisUnited States, Belgium, Canada
-
Dow Pharmaceutical SciencesUnknownPlaque PsoriasisUnited States